• Sample Page

Targeting the ubiquitin–proteasome system for cancer therapy

Tideglusib

Triple-negative breast cancers (TNBCs) are described by too little expression of

August 26, 2018 by Katherine Lewis Leave a Comment

Triple-negative breast cancers (TNBCs) are described by too little expression of estrogen, progesterone, and HER2 receptors. towards the sponsor are accomplished with this agent. Notably, TNBC tumors react to retreatment with PU-H71 for a number of cycles increasing for over 5 weeks without proof level of resistance or toxicity. Through a proteomics strategy, we display … [Read more…]

Posted in: Blogging Tagged: Mouse monoclonal antibody to MECT1 / Torc1, Tideglusib

Lately we identified the “apoptotic ring” containing phosphorylated histone H2AX (γ-H2AX)

July 18, 2017 by Katherine Lewis Leave a Comment

Lately we identified the “apoptotic ring” containing phosphorylated histone H2AX (γ-H2AX) mainly because an early on chromatin modification during apoptosis. to Path. These results implicate MDC1 in the mobile apoptotic response Together. the MDC1 BRCT (breasts cancer C-terminal) site (12) is vital for DDR since it qualified prospects to the next recruitment and set Tideglusib … [Read more…]

Posted in: Blogging Tagged: Rabbit polyclonal to DARPP-32.DARPP-32 a member of the protein phosphatase inhibitor 1 family.A dopamine-and cyclic AMP-regulated neuronal phosphoprotein.., Tideglusib

Copyright © 2026 Targeting the ubiquitin–proteasome system for cancer therapy.

Omega Child WordPress Theme by